Ovarian cancer is detected in 1,400 Australian women every year and takes a toll on roughly 800.

Across the globe, every year, there are 230,000 new ovarian cancer instances and 142,000 deaths are reported.

Now, scientists in Melbourne have discovered a more effectual experiment to diagnose ovarian cancer and expect the tests to begin very soon.

This new trial will check for two extra biomarkers, which might point out ovarian cancer other than traditional tests.

Up till now, levels of CA-125 (cancer antigen 125 or carbohydrate antigen 125) were examined. CA-125 is a biomarker that might be high in the blood of some patients with particular kinds of cancers like ovarian cancer and it offers a correctness of 94% in diagnosing the ailment.

Ovarian cancer specialist, Professor Greg Rice, said that if this new test is successful with the adding up of the new biomarkers, the precision of detection for ovarian cancer might increase from 94 to 97%.

Over 1,150 women globally are to be involved in this trial.

Dr. Rice said, “The idea is to improve the performance of the test, to be looking at its accuracy, to identify women with ovarian cancer hopefully earlier during the course of their disease”.

Australian Ovarian Cancer Specialist, Associate Professor, Lewis Perrin stressed on successful early prognosis of the sickness as the answer.